In the GASTO-1043 study, LC patients receiving CCRT failed to achieve a statistically significant median OS d1ifference after adding Tα1 (34.8 vs. 28.7 months, P=0.062), and in a retrospective analysis examining the function of Tα1 as postoperative adjuvant therapy, LC patients receiving chemoradiotherapy could benefit from OS after Tα1 as adjuvant therapy. The gene discussed is TAAR1; the disease is laryngotracheoesophageal cleft.